The original success of Sildenafil undeniably reshaped the drug landscape, but investing in companies heavily reliant on generic versions presents a complex picture. Despite early profits were impressive, the cessation of patents and the emergence of discounted alternatives have weakened sales. Thus, a thorough analysis of current revenue streams a